BrightSens Diagnostics develops molecular diagnostic tests utilizing ultrabright nanoparticles for rapid and cost-effective screening, diagnosis, and monitoring of cancers and viral diseases. Their technology enables point-of-care testing without the need for PCR, providing early detection and personalized patient monitoring through simple and efficient methods.
Funding
Funding not disclosed
Founders
Product
Problem
Current molecular diagnostic methods, such as PCR, for cancer and viral diseases are limited by long turnaround times and high costs, hindering rapid screening and personalized patient monitoring at the point of care. Existing technologies often require specialized equipment and trained personnel, making them less accessible for decentralized testing.
Solution
BrightSens Diagnostics develops a novel class of molecular diagnostic tests based on ultrabright nanoparticles that enable rapid, simple, and cost-effective screening, diagnosis, and monitoring of cancers and viral diseases at the point of care. The core technology utilizes fluorescent nanoantennas to directly amplify the detection signal of DNA/RNA biomarkers, eliminating the need for enzymatic amplification steps like PCR. This approach allows for highly sensitive and quantitative results to be obtained in minutes using small, portable instruments or even smartphone-based readers. The tests are designed to be adaptable to various targets and compatible with both solid and liquid biopsy samples, offering a versatile solution for decentralized molecular diagnostics.
Target Audience
The primary target audience includes healthcare professionals, hospitals, laboratories, and point-of-care testing providers seeking rapid, cost-effective, and easy-to-use molecular diagnostic solutions for cancer and viral diseases.
Features
- Proprietary ultrabright nanoparticles that act as nanoantennas to amplify fluorescence signals without PCR
- Rapid, quantitative results in minutes, enabling faster clinical decision-making
- Simple, user-friendly assays suitable for point-of-care testing with minimal training
- Adaptable technology that can be customized for various DNA/RNA targets in oncology and virology
- Compatible with a range of sample types, including solid biopsies, blood, and saliva
- Potential for multiplexing to detect multiple biomarkers simultaneously
- Eco-friendly design with reduced reagent consumption and no hazardous materials
- Integration with small, low-cost instruments and smartphone-based applications for decentralized testing